Thus, to understand whether DCs differentially acquire BH-liberated tumor antigen, we separated cDC1s (XCR1+) and cDC2s (XCR1-CD11b+SIRPα+) from the total DC population (gating strategy provided in Figure S7) and measured changes in ZsG expression (Figure 4B) for cDC1s (Figure 4B; Top) and cDC2s (Figure 4B; Bottom) 24 h post-treatment. The gene discussed is XCR1; the disease is neoplasm.